Aurobindo Pharma receives USFDA approval for Sevelamer Carbonate oral suspension

15 Jun 2017 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Sevelamer Carbonate oral suspension, 0.8 gm and 2.4 gm. Sevelamer Carbonate oral suspension, a therapeutic equivalent generic version of Genzyme’s Renvela oral suspension. The product is being launched immediately.

Sevelamer Carbonate oral suspension is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. According to IMS, the approved product has an estimated market size of $140 million for the twelve months ending April 2017.

This is the 116th ANDA (including 19 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 323 ANDA approvals (288 Final approvals including 16 from Aurolife Pharma LLC and 35 tentative approvals) from USFDA.


Aurobindo Pharma Share Price

1090.00 13.90 (1.29%)
23-Apr-2024 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1483.75
Dr. Reddys Lab 5947.30
Cipla 1347.70
Zydus Lifesciences 958.90
Lupin 1580.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.